TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Nov 30, 2020 14:04 JST
Source:
Eisai
Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting
TOKYO, Nov 30, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa), at the 74th American Epilepsy Society Annual Meeting (AES2020), to be held virtually from December 4 to 8, 2020.
A total of 43 poster presentations regarding perampanel are planned, including analysis results from the phase III clinical trial (FREEDOM/Study 342), which evaluated the effectiveness and safety of the perampanel monotherapy in the open-label extension (52 weeks) for epilepsy patients with partial onset seizures (POS) from 12 to 74 years of age without prior treatment history. Additionally, results from the phase III clinical trial Study 311 evaluating safety and tolerability of perampanel as an adjunctive therapy in pediatric epilepsy patients with POS or primary generalized tonic clonic (PGTC) seizures from 4 to less than 12 years of age will be presented.
Perampanel is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. In Japan and the United States, perampanel is currently approved for monotherapy and adjunctive use in the treatment of POS (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older, as well as adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
Eisai considers neurology, including epilepsy, a therapeutic area of focus. As we provide perampanel globally, Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy. Eisai seeks to address the diverse needs of, as well as increase the benefits provided to, patients with epilepsy and their families.
For more information, visit
https://www.eisai.com/news/2020/pdf/enews202080pdf.pdf
.
Source: Eisai
Sectors: BioTech
Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
April 14 2021 12:49 JST
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
April 12 2021 12:16 JST
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
March 31 2021 20:22 JST
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
March 31 2021 20:18 JST
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab
March 30 2021 11:42 JST
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021
March 26 2021 08:16 JST
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan
March 23 2021 17:34 JST
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
March 22 2021 12:13 JST
Eisai Awarded The New Diversity Management Selection 100
March 22 2021 09:38 JST
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders
March 17 2021 10:05 JST
More Press release >>
Latest Press Release
New roads await the Toyota Yaris WRC in Croatia
Apr 16, 2021 18:09 JST
Showa Denko Announces Share Transfer with Change in Subsidiary
Apr 16, 2021 16:30 JST
Fujitsu Updates Group Environmental Plan to Achieve Validation of 1.5 degrees Celcius - Aligned Emissions Reduction Targets, Contribute to Sustainable Future
Apr 16, 2021 10:17 JST
Local Production of Hitachi Automatic Analyzer 3500 to Commence in China
Apr 15, 2021 16:42 JST
NextDecade and Mitsubishi Heavy Industries America Execute Engineering Services Agreement for Carbon Capture at Rio Grande LNG Project in Texas
Apr 15, 2021 13:56 JST
Fujitsu Fuels Big Data Innovation in Mobility Space with Launch of "Digital Twin Collector" Platform
Apr 15, 2021 10:44 JST
Mitsubishi Power Receives Order for Two Gas Turbines for 1,500MW Class GTCC Power Plant in Uzbekistan
Apr 14, 2021 15:36 JST
Honda to Introduce First Energy Service for Europe - e:PROGRESS - in the UK
Apr 14, 2021 15:11 JST
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
Apr 14, 2021 13:49 JST
Mazda3 Named Canadian Car of the Year 2021
Apr 14, 2021 12:47 JST
Tokyo Century and DOCOMO to Globally Expand EDGEMATRIX Edge-AI Platform for Video Surveillance & Monitoring
Apr 13, 2021 17:57 JST
Fujitsu Renews Key Systems for Japan Meteorological Agency, Contributing to Completion of Centralized Virtualization Platform
Apr 13, 2021 15:28 JST
NEC recognized as a Partner of the Year by Juniper Networks for two consecutive years
Apr 13, 2021 11:52 JST
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
Apr 12, 2021 13:16 JST
Fujitsu Embarks on Partnership with Siemens Digital Industries Software Strengthening Global Competitiveness and Accelerating DX to Realize Smart, Sustainable Manufacturing
Apr 12, 2021 11:48 JST
Lexus to Display LF-Z Electrified Concept and New ES
Apr 12, 2021 11:09 JST
MHI Invests in Starfire Energy, a Modular Green Ammonia Solution Provider, to Accelerate Efforts to Energy Transition
Apr 09, 2021 17:22 JST
DENSO Develops Advanced Driver Assistance Products for New Lexus LS, Toyota Mirai
Apr 09, 2021 13:46 JST
Deltacore Capital launches Deltacore Digital Global LP
Apr 09, 2021 13:30 JST
Hitachi Astemo to showcase advanced mobility solutions at Auto Shanghai 2021
Apr 09, 2021 13:05 JST
More Latest Release >>